CaverSTIM, a better alternative for non-responders to oral drugs

[Student]

Hello

https://comphya.com/

[Student]

https://comphya.com/patient-segments/

[Markc2008]

This does sound promising, and would be a great option for those of us that hardly respond to oral meds. It sounds like it’s reversible, your natural penis, and can be used on demand so this is exciting.

[Fourtytwo00]

It looks like a device for nerves injuries. Better said, penis should be OK organically, just nervous stimulus compromised. I don't think it works in case of venous leak or blood flows problems.

[Markc2008]

Agreed. My problem is my nervous system and lack of arousal so yeah I don’t have venous leak but I would say it wouldn’t help for that

[EveningWood]

Hi Student,

Very interesting product.


I read from the provided link that trails have started in early 2021.
Any idea when would this be approved for mass production if successful?

[Student]

Hi eveningwood

I send message to comphya i dont receive answer

[EveningWood]

Hi Student,


Please update this thread if/when you receive an answer, it would be interesting for at least a few people.


Take care,
EveningWood

[Student]

Ok

I will

[Student]

Hi Student,


Please update this thread if/when you receive an answer, it would be interesting for at least a few people.


Take care,
EveningWood

Hello



I find this
It was an article in french i translate with google translate

""""How did 2020 go and what do you plan for 2021?

2020 has surprisingly been a good year for Comphya. Our product has matured, we have consolidated our regulatory and technical file, and we are in the final stages of clinical validation. An independent Clinical Advisory Board is now helping to shape the clinical development of the company and we have increased protection for the patent portfolio. And Comphya raised $ 1.3 million in the form of Bridge Financing - including the loan from FIT.

2021 will be crucial for Comphya, with a clinical trial planned in the United States for patients who have undergone prostatectomy, and another in Switzerland for patients with spinal cord injuries. By the end of 2021, Comphya also aims to raise $ 15 million in Series A to complete the pivotal study, obtain marketing approval and expand the team.

https://www.google.com/amp/s/amp.issuu. ... s/11732832